Mainz Biomed, Liquid Biosciences License mRNA Cancer Test Technology

Mainz Biomed has entered an exclusive licensing agreement with Liquid Biosciences to develop a blood-based test for the non-invasive detection of pancreatic cancer using novel mRNA biomarkers. This collaboration aims to leverage the EMERGE platform and AI algorithms to enhance the sensitivity and specificity of the detection, achieving 95% sensitivity and 98% specificity in initial studies. Meanwhile, advances in mRNA technology are being explored in oncology, with researchers, including Dr. Vinod Balachandran, showing promising results for personalized mRNA vaccines that may mobilize anti-tumor T cells against pancreatic cancer. A recent study highlights a therapeutic mRNA vaccine that activates immune responses lasting up to four years, potentially reducing recurrence risk. Such developments represent a significant shift in the treatment landscape for pancreatic cancer, traditionally known for its poor prognosis. These innovations reflect a growing optimism in the fight against this aggressive disease.